Suraksha Diagnostic · risk themes across the available quarters.
Bear-case history
Analyst flagged declining EBITDA margins in mature centers (42 centers) on Slide 10. Management attributed this to seasonal weakness in Q3, which is the weakest quarter in healthcare, but did not provide specific margin data for mature centers.
Listed diagnostic players Dr. Lal and Metropolis are introducing genomics capabilities. While management claims Suraksha's first-mover advantage in eastern India with turnaround time benefits, larger competitors have greater resources to scale genomic offerings.
PPP projects face pricing pressure, receivables issues, and are low-margin. Management stated they are not actively seeking PPP projects and will deploy capital in other centers, though they sometimes accept when forced.
Management struggled to quantify steady-state revenue contribution from genomics by FY28, calling it difficult to put a number to. Revenue currently at nascent stage with ₹53 lakh quarterly run rate against total revenue of ₹78 crore.